ArticleOncoimmunology
Identification of neoantigen-specific T cells and their targets: implications for immunotherapy of head and neck squamous cell carcinoma.
Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 36 citations in OpenAlex.
- Precision immuno-oncology in oral cancer: latest trends in biomarkers, novel drug development and nanoparticle-based therapeutic platforms.Frontiers in cell and developmental biology · 2026Review
- Trends in immunotherapy for oral squamous cell carcinoma.Cellular oncology (Dordrecht, Netherlands) · 2025Review
- Neoantigen-based immunotherapy: advancing precision medicine in cancer and glioblastoma treatment through discovery and innovation.Exploration of targeted anti-tumor therapy · 2025Review
- FOXM1/DEPDC1 feedback loop promotes hepatocarcinogenesis and represents promising targets for cancer therapy.Cancer science · 2024Article
- Identification of T Cell Receptors Targeting a Neoantigen Derived from Recurrently Mutated FGFR3.Cancers · 2023Article
- Unveiling the interplay between mutational signatures and tumor microenvironment: a pan-cancer analysis.Frontiers in immunology · 2023Article
- Rapid generation of genetically engineered T cells for the treatment of virus-related cancers.Cancer science · 2022Article
- Neoantigens and their clinical applications in human gastrointestinal cancers.World journal of surgical oncology · 2022Review
- Tumor RNA transfected DCs derived from iPS cells elicit cytotoxicity against cancer cells induced from colorectal cancer patients in vitro.Scientific reports · 2022Article
- Calreticulin as a prognostic biomarker and correlated with immune infiltrate in kidney renal clear cell carcinoma.Frontiers in genetics · 2022Article
- dbPepNeo2.0: A Database for Human Tumor Neoantigen Peptides From Mass Spectrometry and TCR Recognition.Frontiers in immunology · 2022Article
- Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types.Journal for immunotherapy of cancer · 2021Article
- Immunogenomics in personalized cancer treatments.Journal of human genetics · 2021Review
- Functional analysis of peripheral and intratumoral neoantigen-specific TCRs identified in a patient with melanoma.Journal for immunotherapy of cancer · 2021Article
- Generation of neoantigen-specific T cells for adoptive cell transfer for treating head and neck squamous cell carcinoma.Oncoimmunology · 2021Article
- Precision and Immunoprevention Strategies for Tobacco-Related Head and Neck Cancer Chemoprevention.Current treatment options in oncology · 2021Review
- Review
- Advances in identification and selection of personalized neoantigen/T-cell pairs for autologous adoptive T cell therapies.Oncoimmunology · 2021Review
- Calreticulin and cancer.Cell research · 2021Review
- Point mutation screening of tumor neoantigens and peptide-induced specific cytotoxic T lymphocytes using The Cancer Genome Atlas database.Oncology letters · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To develop a practically applicable method for T-cell receptor (TCR)-engineered T cell immunotherapy targeting neoantigens, we have been attempting to identify neoantigen-specific T cell receptors (TCRs) and establish TCR-engineered T cells in a 3-4-month period. In this study, we report the characterization of T cell repertoires in tumor microenvironment (TME) and identification of neoantigen-specific TCRs after stimulation of patient-derived T cells. We screened 15 potential neoantigen peptides and successfully identified two CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.